INR Monitoring Frequency for Patients on Long-Term Warfarin Therapy for Rheumatic Heart Disease

Initial Monitoring Schedule

The American Geriatrics Society recommends daily INR monitoring until a steady state is achieved (typically 5-7 days) 2, 3
The American Geriatrics Society suggests two to three times weekly for 1-2 weeks 2, 3
The American Geriatrics Society advises weekly for 1 month 2, 3
The American Geriatrics Society recommends monthly for 1-2 months 2, 3
The American Geriatrics Society recommends every 1-2 months if stability is maintained 2, 3

For patients with consistently stable INRs, the American College of Cardiology supported approach allows testing frequency to be extended up to 12 weeks 4

The American Geriatrics Society recommends a target INR of 2.0 to 3.0 for patients with RHD and atrial fibrillation or previous embolic events 1
The American Geriatrics Society recommends a target INR of 2.5 to 3.5 for patients with mechanical heart valves 1

Changes in diet and weight require more frequent monitoring, as recommended by the American Geriatrics Society and the American College of Cardiology 2, 4
Changes in concomitant medications, particularly antibiotics, necessitate more frequent monitoring, according to the American Geriatrics Society and the American College of Cardiology 2, 3, 4
Intercurrent illness requires more frequent monitoring, as advised by the American Geriatrics Society and the American College of Cardiology 2, 4
Any indication of minor bleeding requires more frequent monitoring, according to the American Geriatrics Society and the American College of Cardiology 2, 4
Changes in baseline INR values require more frequent monitoring, as recommended by the American Geriatrics Society and the American College of Cardiology 2, 4
After warfarin dose adjustments, more frequent monitoring is necessary, as suggested by the American College of Cardiology 4

Older adults may require more frequent monitoring due to potentially increased risk of hemorrhage and greater fluctuations in INR, as noted by the American Geriatrics Society 3, 5

Failing to increase monitoring frequency when changes occur that might affect INR stability is a common pitfall, as warned by the American Geriatrics Society and the American College of Cardiology 2, 4
Not ensuring adequate follow-up when transitioning between care settings is a pitfall to avoid, according to the American College of Cardiology 6

For INRs slightly out of range (±0.5 from target), dose adjustment may not be necessary; continue current dose and retest within 1-2 weeks, as recommended by the American College of Cardiology 4
For more significant deviations, dose adjustments and more frequent monitoring are required, as advised by the American Geriatrics Society 2, 3